Navegando por Palavras-chave "medula óssea"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosAvaliação da modulação de células-tronco hematopoéticas por fragmentos sintéticos da leptina(Universidade Federal de São Paulo (UNIFESP), 2014-09-24) Dias, Carolina Carvalho [UNIFESP]; Gamero, Edgar Julian Paredes Gamero [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Leptin is a cytokine composed of 167 a i o acids first described as a satiety hormone that regulates body weight and energy expenditure. In the body, leptin has numerous functions in different tissues. In hematopoiesis, previous studies have demonstrated its potential in the differentiation and/or cell proliferation. The group of Dr. Antonio de Miranda, from Department of Biophysics of UNIFESP, has developed human and murine leptin synthetic peptide fragments, whose sequences included portions of the a helical region of the leptin molecule. Two of these human sequence peptides, Ac-hLEP92-11S-NH2and Ac-[Ser117]-hLEP116_140- NH2 have shown activity in a similar manner to the entire protein. Additionally, similar results were obtained with another homologous peptide sequence of mouse, the Ac-mLEP98-122-NH2.This study aimed to evaluate the modulation of hematopoiesis by human and murine synthetic peptides (based on sequences previously tested). The human, Ac-[Ser117]-hLEP116_140-NH2(LEP5), and murine, Ac-mLEP110-119-NH2(LEPF), sequence induced an increase of hematopoietic stem cell (HSC) and clonogenic capacity, as well as, activated Jak2 in HSC. Moreover, the fragment LEPF improved the engraftment of HSC after radiation, however did not accelerate bone marrow regeneration after the chemotherapy with 5-FU. The fragment LEPF only increased HSC after 5-FU treatment. Thus, the bioactive synthetic fragments of leptin could be used to improve the engraftment of HSC is some clinical situation such as HSC transplantation.
- ItemAcesso aberto (Open Access)Histologia da medula óssea(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2009-01-01) Alves, Antonio Correa [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)The bone marrow biopsy after the introduction of the Jamshidi needle has come into a routine practice due to the facilitation to obtain good sample. Due to the adequate size of the sample, the decalcification time decreased and consequently the histological quality improved allowing to the pathologist a more deep and precise morphological interpretation and diagnosis of the hematological and non- hematological disorders. For a correct diagnosis, the pathologist should be acquainted with the normal histology of the bone marrow parenchyma, it variations depending on age, as well as with the clinico- laboratorial data to integrate them with the morphological features.
- ItemAcesso aberto (Open Access)Indicações de transplante de células-tronco hematopoéticas em pediatria: consenso apresentado no I Encontro de Diretrizes Brasileiras em Transplante de Células-Tronco Hematopoéticas - Sociedade Brasileira de Transplante de Medula Óssea, Rio de Janeiro, 2009(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2010-01-01) Seber, Adriana [UNIFESP]; Bonfim, Carmem Maria S.; Daudt, Liane E.; Gouveia, Roseane Vasconcelos [UNIFESP]; Ginani, Valéria C. [UNIFESP]; Mauad, Marcos; Castro Jr, Claudio G.; Universidade Federal de São Paulo (UNIFESP); Universidade Federal do Paraná; UFRGS; Hospital Amaral Carvalho; Hospital de Clínicas de Porto AlegreThe Brazilian Bone Marrow Transplant Society (SBTMO) held its First Meeting on Bone Marrow Transplant Guidelines in 2009. A working group of hematologists and oncologists with experience in pediatrics was formed to review evidence-based indications for pediatric transplants. Scientific publications were carefully assessed and, for each disease, the evidence for recommendation (from A to C) and the quality of the evidence (from 1 to 3) were defined. The recommendations include malignant and non-malignant hematological diseases, solid tumors, immunodeficiency, and storage diseases treated with hematopoietic stem cell transplants: either autologous or allogeneic from matched sibling donors or unrelated donors (adults or umbilical cord blood). Guidelines for reduced-intensity transplants, manipulated grafts or partially compatible donors were not included as there are no uniformly accepted recommendations. All indications are based on the best current knowledge which may change over time. Thus, this review should not be directly applied to patient care without taking into account the disease, donor and patient characteristics. Additionally, this paper should not be used as a document to limit patient access to transplant if correctly indicated. In this review we also point out differences between transplantation in adults and children and make some specific recommendations for pediatric transplants.
- ItemAcesso aberto (Open Access)Transplante de células-tronco hematopoéticas e leucemia mieloide aguda: diretrizes brasileiras(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2010-05-01) Silla, Lucia Mariano R.; Dulley, Frederico; Saboya, Rosaura; Paton, Eduardo; Kerbauy, Fábio Rodrigues [UNIFESP]; Arantes, Adriano de Moraes [UNIFESP]; Hamerschlak, Nelson; Hospital de Clínicas de Porto Alegre Serviço de Hematologia e Transplante de Medula Óssea; Universidade de São Paulo (USP); Hospital de Câncer de Barret Hemonúcleo; Universidade Federal de São Paulo (UNIFESP); Associação de Combate ao Câncer em Goiás Hospital Araújo Jorge Serviço de Transplante de Medula Óssea; Hospital Israelita Albert Einstein Programa de Hematologia e Transplante de Medula ÓsseaThe objective of this work was to define guidelines for the indication of hematopoietic stem cells transplantation (HSCT) in the treatment of acute myeloid leukemia (AML) in Brazil. The role of HSCT in the treatment of AML was discussed by the authors and presented to the Brazilian Society of Bone Marrow Transplantation in a meeting to formulate and ratify the Brazilian Guidelines on HSCT. This consensus was based on a review of international publications and on the Brazilian experience in HSCT for the treatment of AML. The optimal treatment for AML in first complete remission (1CR) has not been defined yet. There is consensus on the indication of allogeneic HSCT with myeloablative conditioning for patients who present high risk cytogenetic changes. Allogeneic HSCT is not indicated for low cytogenetic risk 1RC patients and, apparently, allogeneic and autologous HSCT and consolidation chemotherapy are similar for intermediate risk patients.